Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000061785

Apexbio Technology LLC ARN-509 956104-40-8 10mM (in 1mL DMSO)
SDP

Catalog No. 5000061785
Encompass_Preferred

ARN-509 is a synthetic biaryl thiohydantoin derivative acting as a competitive inhibitor of the androgen receptor (AR) It binds AR with an IC50 of approximately 16 nmol/L blocking receptor-mediated signaling pathways implicated in prostate cell proliferation Androgen receptor is a nuclear hormone receptor crucial for male sexual differentiation and prostate cancer cell growth Overexpression or hyperactivation of AR frequently occurs in castration-resistant prostate cancer Experimental data indicate that ARN-509 treatment reduces AR-driven transcription and inhibits cell proliferation in prostate cancer cell lines such as LNCaP and VCaP In murine xenograft models oral dosing of ARN-509 diminishes androgen-dependent reporter gene activity reduces tumor cell proliferation and induces apoptosis ARN-509 is utilized in biomedical research to investigate AR signaling and prostate cancer therapeutics

Catalog No. 50-000-61785 Supplier Apexbio Technology LLC Supplier No. A83645.1
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

ARN-509 is a synthetic biaryl thiohydantoin derivative acting as a competitive inhibitor of the androgen receptor (AR) It binds AR with an IC50 of approximately 16 nmol/L blocking receptor-mediated signaling pathways implicated in prostate cell proliferation Androgen receptor is a nuclear hormone receptor crucial for male sexual differentiation and prostate cancer cell growth Overexpression or hyperactivation of AR frequently occurs in castration-resistant prostate cancer Experimental data indicate that ARN-509 treatment reduces AR-driven transcription and inhibits cell proliferation in prostate cancer cell lines such as LNCaP and VCaP In murine xenograft models oral dosing of ARN-509 diminishes androgen-dependent reporter gene activity reduces tumor cell proliferation and induces apoptosis ARN-509 is utilized in biomedical research to investigate AR signaling and prostate cancer therapeutics

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.